Cendakimab

DRUG4 trials

Sponsors

Celgene International II S.a.r.l., Celgene, Bristol-Myers Squibb

Conditions

Eosinophilic EsophagitisEosinophilic esophagitisHealthy ParticipantsHealthy Volunteers

Phase 1

A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

CompletedNCT05175352

CelgeneEosinophilic Esophagitis

Start: 2022-06-07End: 2024-10-11Updated: 2024-12-20

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

CompletedNCT05337345

Bristol-Myers SquibbHealthy Volunteers

Start: 2022-05-02End: 2022-12-15Updated: 2023-02-10

A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants

CompletedNCT05638282

Bristol-Myers SquibbHealthy Participants

Start: 2023-02-15End: 2023-06-27Updated: 2023-08-01

Phase 3

"A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS"

CompletedCTIS2023-506278-10-00

Celgene International II S.a.r.l.Eosinophilic esophagitis

Start: 2022-04-22End: 2025-08-11Target: 54Updated: 2025-08-25

Related Papers

Pharmacokinetic Characterization of Cendakimab Administered with Different Devices and at Different Injection Sites in Healthy Participants.

2025-05-15